key: cord-0970432-2xziqfk6
authors: Kabbani, Mariam; Poskin, Maud; Benhadou, Farida
title: Psoriasis exacerbation after COVID‐19 vaccination in high‐risk group: How to manage it?
date: 2022-02-17
journal: Dermatol Ther
DOI: 10.1111/dth.15368
sha: 70c96cd65c6c8b35235c0640eda05cf48499d761
doc_id: 970432
cord_uid: 2xziqfk6

nan

demic, the COVID-19 vaccination campaigns represent an essential step toward achieving this goal, thereby not only decreasing the mortality and morbidity of this virus, but possibly eliminating it. 1 Nonetheless, growing evidence suggests that COVID-19 vaccines may be associated with a wide range of cutaneous reactions. 2 Recently, these vaccines have also been linked to new onset and flare-up of preexisting psoriasis, all of which attained complete clearance after the use of standard treatments. 3, 4 Herein, we report the case of a 53-year-old man with severe plaque psoriasis since 2016, who had been previously but unsuccessfully treated with topical steroids, UV-therapy, methotrexate, adalimumab, secukinumab, guselkumab and apremilast. The patient, a heavy smoker, had been suffering from several comorbidities 19 vaccine. Psoriasis has long been proven to be a Th1-mediated chronic disorder whose pathogenesis is dominated by the IL-23/IL-17 axis. 5 As for the BNT162b2 vaccine, it had been proven that in addition to inducing humoral immunity in humans, it can also stimulate Th1 cells. 6 Moreover, animal models have recently demonstrated that COVID-19 mRNA vaccines can lead to production of IL-17. 7 

None.

The data that support the findings of this study are available on request from the corresponding author. The data are not publicly available due to privacy or ethical restrictions. 

Toward achieving a vaccine-derived herd immunity threshold for COVID-19 in the U.S. Front Public Health

Cutaneous findings following COVID-19 vaccination: review of world literature and own experience

New-onset and exacerbations of psoriasis after mRNA COVID-19 vaccines: two sides of the same coin?

Psoriasis flare-up associated with second dose of Pfizer-BioNTech BNT16B2b2

COVID-19 mRNA vaccine

Dendritic cells: the driver of psoriasis

BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans

SARS-CoV-2 vaccines elicit durable immune responses in infant rhesus macaques

Psoriasis flare after influenza vaccination in Covid-19 era: a report of four cases from a single center

Comprehensive investigations revealed consistent pathophysiological alterations after vaccination with COVID-19 vaccines

https://orcid.org/0000-0002-3897-7090